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 Background: Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis B virus (HBV) infec-
tion after liver transplantation using hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogue (NUC) 
prophylaxis.
 Material/Methods: Data from 371 adults transplanted for HBV-related disease at 20 European centers and given HBIg for ³12 
months ± NUC therapy were analyzed retrospectively.
 Results: HBIg comprised Hepatect® (iv HBIgB; n=299), subcutaneous Zutectra® (sc HBIg, n=236), and other HBIg prepa-
rations (n=130); 93.5% received NUC therapy. Mean follow-up was 6.8±3.5 years. The primary efficacy variable, 
freedom from HBV recurrence, occurred in 95.7% of patients (95% CI [93.1%, 97.5%]). The observed incidence 
of recurrence was 16/371 (4.3%) (annual rate 0.65%); 5/16 patients with recurrence had discontinued HBIg 
and 7/16 had anti-HBs <100 IU/l. Excluding these 7 patients, the HBV recurrence rate was 2.4%. The recurrence 
rate while on HBIg therapy was 1 per 2069 months. In patients who discontinued HBIg, risk of HBV recurrence 
versus sc HBIg users was increased by 5.2-fold (1 per 1 603 versus 1 per 8379 treatment months). The annual 
rate of HBV-related hepatocellular carcinoma (HCC) recurrence was 1.7%.
Authors’ Contribution: 
Study Design A
 Data Collection B
 Statistical Analysis C
Data Interpretation D
 Manuscript Preparation E
 Literature Search F
Funds Collection G
1 Department of Gastroenterology and Hepatology, University Hospital Münster, 
Münster, Germany
2 Department of Gastroenterology and Hepatology, University Hospital Essen, 
Essen, Germany
3 Corporate Medical Affairs and Corporate Clinical Research and Development, 
Biotest AG, Dreieich, Germany
4 Cambridge Liver Unit, Addenbrooke’s Hospital, Cambridge, U.K.
5 Hepatobiliary Surgery and Liver Transplantation, Chirurgia Epatica e del Trapianto 
Fegato Pisa, Pisa, Italy
6 Department of Gastroenterology and Hepatology, Erasmus Medical Center, 
Rotterdam, The Netherlands
7 Department of Gastroenterology and Rheumatology, University of Leipzig, Leipzig, 
Germany
8 Swiss HPB Center and Gastroenterology and Hepatology, University Hospital 
Zürich, Zürich, Switzerland
9 Transplantation Centre and Service of Gastroenterology and Hepatology, 
Lausanne, Switzerland
10 Chirurgia Generale 2U, Centro Trapianto Fegato, AO Città della Salute e della 
Scienza di Torino, Turin, Italy
11 Hepatology and Gastroenterology Unit, ISMETT-IRCCS, Palermo, Italy
12 Department of General Surgery, Morgagni-Pierantoni General Hospital, 
University of Bologna, Bologna, Italy
13 Surgery and Abdominal Transplantation Division, Niguarda Ca’ Granda Hospital, 
Milan, Italy
14 Multivisceral Transplant Unit, Padua University Hospital, Padua, Italy
15 University Clinic for Visceral Surgery and Medicine, Inselspital, Bern, Switzerland
16 Department of General Surgery and Organ Transplantation, Umberto I Policlinic, 
Sapienza University, Rome, Italy
17 Multivisceral Transplant Unit, Gastroenterology, Department of Surgery, 
Oncology and Gastroenterology, University Hospital of Padua, Padova, Italy
18 Department of Visceral and Transplantation Surgery, University Hospital RWTH 
Aachen, Aachen, Germany
19 Department of Hepatobiliary and Transplant Surgery, University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany
20 Transplant Centre, Faculty of Medicine, Azienda Ospedaliera Policlinico Tor 
Vergata, Rome, Italy
e-ISSN 2329-0358
© Ann Transplant, 2018; 23: 789-801 
DOI: 10.12659/AOT.910176
789
Indexed in: [Science Citation Index Expanded] [Index Medicus/MEDLINE] 
[Chemical Abstracts] [Scopus]
ORIGINAL PAPER
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Background
Chronic hepatitis B virus (HBV) infection is a leading cause of 
cirrhosis and hepatocellular carcinoma (HCC) and is a major 
cause of mortality worldwide [1]. Although antiviral therapy 
with nucleos(t)ide analogues (NUCs) can prevent the need for 
transplantation in as many as 35% of patients with decom-
pensated HBV-related cirrhosis, HBV infection remains a major 
indication for liver transplantation [2]. Due to the favorable 
impact of antiviral treatment on decompensated disease, the 
proportion of wait-listed HBV-positive patients who have HBV-
related HCC (HBV-HCC) has increased, while decompensated 
HBV-disease has become less frequent [3]. Following transplan-
tation, combined prophylactic treatment with hepatitis B im-
munoglobulin (HBIg) and NUC therapy has profoundly reduced 
the risk of HBV recurrence [4], substantially improving graft 
and patient survival rates [2], and is considered the standard 
of care in this setting [5]. HBIg therapy is usually started intra-
venously for at least 1 week post-transplant, after which it can 
be switched to subcutaneous or intramuscular preparations.
Although highly effective, even combined prophylactic therapy 
cannot entirely prevent recurrence of HBV infection after 
liver transplantation. A systematic review of 46 studies by 
Cholongitas and colleagues, involving over 2000 HBV-positive 
patients treated with HBIg and NUC therapy (lamivudine and/
or adefovir), showed recurrence in 6.6% of cases [6]. Patients 
with HBV-HCC appear to be at higher risk for HCC recurrence 
than those with non-HBV-HCC [7], and a recurrence rate of 
14.8% has been reported even under HBIg and NUC therapy [8]. 
The available evidence relating to HBV or HBV-HCC recur-
rence, however, is typically based on single-center cohorts of 
fewer than 100 patients [6]. Follow-up times are often short 
(mean 21 months in the 46 studies included in the analysis by 
Cholongitas et al) [6], but the average time to recurrence has 
been reported to be up to 44 months for HBV infection [9] and 
~26 months for HBV-HCC [8]. Moreover, most estimates are 
derived from populations in which ongoing prophylaxis with 
both HBIg and NUC therapy was mandatory for inclusion. This 
does not necessarily reflect routine practice, in which HBIg is 
withdrawn in low-risk patients by some centers.
An international, multicenter retrospective analysis was un-
dertaken to evaluate the recurrence of HBV infection and to 
assess other clinical and serological efficacy endpoints during 
long-term follow-up in a large cohort of patients who had un-
dergone liver transplantation for HBV-related disease.
Material and Methods
Study design
A retrospective analysis was performed at 20 liver transplant 
centers in Italy, Germany, Switzerland, the Netherlands, and 
the United Kingdom. The inclusion period was from January 
2000 to May 2016. From a list of eligible patients, 50% of pa-
tients with HBV-HCC and 50% without HCC were to be selected 
randomly for documentation, stratified by year of transplant. 
Random selection was performed centrally. It was planned to 
recruit approximately 400 patients, with an average of 20–25 
patients per center (approximately 200 from Italy and approxi-
mately 200 in total from Germany, Switzerland, the Netherlands 
and the United Kingdom).
For patients not alive at time of documentation, no demo-
graphic characteristics were collected except for the year of 
birth. Approval from the Institutional Review Board was ob-
tained for all sites and all living patients signed informed con-
sent before data were collected.
Eligibility criteria
Patients were eligible for inclusion if they were aged ³18 
years and had undergone primary transplantation for fulmi-
nant hepatitis B, hepatitis B cirrhosis, or HBV-HCC inside the 
Milan criteria, or liver re-transplantation except due to HBV 
recurrence, from 2000–2014. All patients were required to 
have received treatment with HBIg for at least 1 year during 
the post-transplant period, including a minimum of 6 months’ 
treatment with intravenous Hepatect® CP (iv HBIgB, Biotest 
AG, Dreieich, Germany) or subcutaneous Zutectra® (sc HBIg, 
Biotest AG, Dreieich, Germany), with or without concomitant 
NUC therapy, and to have a minimum of 1 year’s data available. 
Patients could receive more than 1 HBIg therapy.
 Conclusions: These results support the long-term use of HBIg with NUC therapy as an effective management strategy to 
minimize risk of HBV recurrence and virus-related complications after liver transplantation.
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Data collection
Data were captured from clinical documentation and patients’ 
hospital records at time of transplant, and after transplanta-
tion until the end of the documentation period. Documentation 
was obtained for a minimum of 1 year and a maximum of 10 
years post-transplant. Demographic and clinical data at the 
point of transplantation were recorded (unless unavailable for 
deceased patients). Any HBV recurrence during the documen-
tation period was captured, defined as detection of hepatitis B 
surface antigen (HBsAg), and/or HBV DNA in the serum based 
on licensed diagnostic test systems for HBV. Additionally, all 
pre- or post-transplant measurements of antibodies against 
hepatitis B surface antigen (anti-HBs) or core antigen (anti-
HBc), HBsAg, and HBV DNA were recorded. All clinical signs 
of HBV recurrence (e.g., jaundice) were documented, as well 
as recurrence of HBV-HCC or development of de novo malig-
nancies other than HCC. Liver and kidney function test results 
were recorded pre-transplant and, if applicable, at the time of 
HBV recurrence. Individual adverse drug reaction reporting was 
not performed other than routine spontaneous adverse drug 
documentation by the treating physician via standard phar-
macovigilance procedures.
Study endpoints
The primary efficacy variable was the proportion of patients 
free from HBV recurrence, as assessed by non-detectability of 
HBsAg and/or HBV DNA in serum during the documentation 
period. Secondary efficacy variables were the proportion of pa-
tients with HBV recurrence, the time to HBV recurrence, the 
proportion of patients with HBV-HCC recurrence, and serum 
levels of anti-HBs, HBsAg, and HBV DNA. Other efficacy vari-
ables included viral status, exposure time to different HBIg 
therapies, use of different antiviral treatments, immunosup-
pressive treatments, graft rejection (acute and chronic), and 
occurrence of de novo malignancies other than HCC. There 
were no safety variables.
Statistical analysis
No formal sample size calculation was performed. For the pri-
mary endpoint a 2-sided 95% confidence interval (CI) was 
calculated based on the Clopper-Pearson method. Two-sided 
95% CIs were also calculated for the percentages of patients 
with HBV recurrence, HBV-HCC recurrence, or occurrence of 
any new non-HCC malignancy during the period of documen-
tation. Times to first HBV recurrence, HBV-HCC recurrence, or 
onset of any de novo malignancy (non-HCC) were estimated 
by the Kaplan-Meier method. All analyses were performed 
using SAS® version 9.3.
Results
Study population
In total, 371 patients met all eligibility criteria and were included 
in the analysis (Figure 1). Of the 332 who were alive at the time 
of study initiation, 257 were male (77.4%) and the mean (±SD) 
age was 58.5 (±10.7) years (data were not available for de-
ceased patients). Characteristics of the study population overall, 
and for the subgroup for whom the primary indication for liver 
transplantation was HBV-HCC (n=147), are shown in Table 1. 
Five patients with HBV-HCC as the primary indication for 
transplantation who underwent downstaging pre-transplant 
were formally outside the Milan criteria according to the doc-
umented radiological results. Since the histology results indi-
cated successful downstaging and the participating physicians 
considered all patients to be inside the Milan criteria at the 
time of liver transplantation, the patients were not excluded 
from the analysis.
Among patients in whom serological data were available 
before liver transplantation, 183/227 (80.6%) were anti-HBc 
positive, 279/300 (93.0%) were HBsAg-positive, and 101/239 
(42.3%) had detectable levels of HBV DNA. For donors in whom 
data were available, 36/131 (27.5%) were anti-HBs-positive, 
53/264 (20.1%) were anti-HBc-positive, and 4/279 (1.4%) were 
HBsAg-positive.
371 patients analyzed
101 patients not
receiving HBIg
therapy at
last documentation
270 patients
receiving HBIg
therapy at last
documentation
iv HBIgB n=37
sc HBIg n=205
Other HBIg n=28
During documentation:
iv HBIgB n=299
sc HBIg n=236
Other HBIg n=130
39 patients died before study start
HCC n=14
Cardiovascular discorders n=9
Non-HCC malignancy n=6
HBV infection-related
complications n=2
Other n=8
Figure 1.  Flow diagram of the 371 patients transplanted for 
hepatitis B virus (HBV)-related disease who were 
included in the analysis, of whom 332 (89.5%) were 
alive at the time of study entry. More than 1 type of 
hepatitis B immunoglobulin (HBIg) could be given 
(iv HBIgB, sc HBIg, or other licensed HBIg preparations). 
By the final documentation, 270/332 patients (81.3%) 
were receiving HBIg therapy. HCC, hepatocellular 
carcinoma.
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All HBV patients (n=371) HBV-HCC (n=147)
At Time of Transplant
Primary indication for liver transplant, n (%)
 HBV-related liver cirrhosis
 HBV-HCC
 HBV-related fulminant hepatitis
 195 (52.6)
 147 (39.6)
 29 (7.8)
 0
 147 (100.0)a
 0
HBsAg-positive, n/N (%) 279/300 (93.0) 114/125 (91.2)
HBV DNA-positive, n/N (%)
 Serum trough level, copies/mL, median (range)
101/239 (42.3)
2.7×103
(0.2, 2.35 1011)
48/104 (46.1)
1.93×103
(10.0, 2.35 1011)
Previous liver transplantation, n (%)  7 (1.9)  3 (2.0)
Decompensated liver disease, n (%)  191 (51.5%)  38 (25.9)
Type of transplant, n (%)
 Whole liver
 Split liver, living donor
 Split liver, deceased donor
 Combined liver and kidney
 342 (92.2)
 13 (3.5
 12 (3.2)
 4 (1.1)
 135 (91.8)
 2 (1.4)
 4 (2.7)
 6 (4.1)
MELD score at time of transplant, mean (±SD)  18.0 (±9.2)  14.7 (±7.2)
Viral co-infection, n (%)
 Hepatitis D 
 Hepatitis C 
 114 (30.7)
 37 (10.0)
 37 (25.2)
 15 (10.2)
Concomitant liver disease, n (%)
 Alcoholic liver disease
 Non-alcoholic steatohepatitis
 Autoimmune hepatitis
 Primary biliary cholangitis
 41 (11.1)
 3 (0.8)
 3 (0.8)
 1 (0.3)
 16 (10.9)
 1 (0.7)
 2 (1.4)
 0
Concomitant non-hepatic disease, n (%)
 Diabetes mellitus
 Arterial hypertension
 Kidney disease
 Allergy
 Non-HCC malignanciesb
 49 (13.2)
 34 (9.2)
 27 (7.3)
 15 (4.0)
 7 (1.9)
 24 (16.3)
 25 (17.0)
 12 (8.2)
 7 (4.8)
 2 (1.4)
Nucleos(t)ide analogue, n (%)c  217 (58.5)  108 (73.5)
After Transplantation
Induction therapy
 Anti-IL-2 receptor antibody
 Rabbit antithymocyte globulin
 36 (9.7)
 9 (2.4)
 20 (13.6)
 4 (2.7)
Initial maintenance immunosuppression post-transplant, n (%)
 Calcineurin inhibitors
 Corticosteroids
 Mycophenolate mofetil
 Azathioprine
 mTOR inhibitors
 Sotrastaurin
 348 (93.8)
 253 (68.2)
 140 (37.7)
 35 (9.4)
 25 (6.7)
 3 (0.8)
 142 (96.6)
 108 (73.5)
 68 (46.3)
 11 (7.5)
 16 (10.9)
 2 (1.4)
Table 1.  Patient characteristics in the total HBV study population and in the subpopulation in whom HCC was the primary indication 
for transplantation.
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The most frequent immunosuppressive agents in the initial 
post-transplant maintenance regimen were calcineurin inhib-
itors (93.8%), mycophenolate mofetil (37.7%), and corticoste-
roids (68.2%) (Table 1) and these percentages were 82.7%, 
31.3%, and 28.6%, respectively, at the last documentation.
The mean (±SD) follow-up time was 6.8 (±3.5) years (median 
7.0 years, range 1.0–15.1 years). The total observation period 
across all patients was 30 781 months, including time with or 
without HBIg treatment. The mean (±SD) survival time was 
6.8 (±3.5) years.
HBIg therapy
All patients received intravenous HBIg immediately after trans-
plantation, except for 2 patients who were given sc HBIg. In 
total, iv HBIgB was given to 299/371 patients (80.6%). At least 
1 change in HBIg therapy occurred in 250 patients (67.4%), 
with 179, 47, 17, 4, and 3 patients changing 1, 2, 3, 4, or 5 
times, respectively. After initial intravenous therapy, a total of 
236 patients (63.6%) were switched to sc HBIg (Table 2). One 
hundred and thirty patients (35.0%) received another HBIg 
product, including intramuscular Igantibe® (Instituto Grifols 
S.A., Barcelona, Spain) and intravenous Niuliva® (Instituto 
Grifols S.A., Barcelona, Spain). At the end of documentation, 
270/371 patients (73.8%) were still receiving HBIg therapy (iv 
HBIgB n=37, sc HBIg n=205, other HBIgs n=28).
The mean duration of exposure was 30.8, 36.4, and 42.1 months 
for iv HBIgB, sc HBIg, and other HBIgs, respectively, with total 
treatment durations of 8993, 8379, and 5392 months. For 
a total of 8017 months, no HBIg treatment was given. The 
median time to starting therapy was 1 day for iv HBIgB com-
pared to 847 days for sc HBIg and 208 days for other therapies. 
The median daily dose of iv HBIgB (238 IU, range 12–10 000) 
was higher than for sc HBIg (71 IU, range 16–143) or other 
HBIgs (71 IU, range 16–5000), reflecting use of higher dosing 
in the early post-transplant period (Figure 2A). From month 3 
Table 1 continued.  Patient characteristics in the total HBV study population and in the subpopulation in whom HCC was the primary 
indication for transplantation.
All HBV patients (n=371) HBV-HCC (n=147)
Nucleos(t)ide analogue, n (%)
 Lamivudine
 Entecavir
 Tenofovir
 Adefovir
 Telbivudine
 347 (93.5)
 225 (60.6)
 87 (23.5)
 87 (23.5)
 54 (14.6)
 3 (0.8)
 145 (98.6)
 82 (55.8)
 45 (30.6)
 33 (22.4)
 27 (18.4)
 1 (0.7)
a HBV-HCC histopathology on explant in 118/135 patients in whom data was available. b Previous B-cell lymphoma/seminoma, 
neuroendocrine tumor of the pancreas (patient transplanted for HCC), Waldenström’s macroglobulinemia, previous urothelial 
carcinoma, adenocarcinoma of the right colon (patient transplanted for HCC), ependymoma, yolk sac tumor. c Lamivudine, entecavir, 
tenofovir, adefovir or telbivudine. HBsAg – hepatitis B surface antigen; HBV – hepatitis B virus; HCC – hepatocellular carcinoma; 
mTOR – mammalian target of rapamycin; MELD – model for end-stage liver disease; n/N – number of patients with 
characteristic/number of patients with data available.
iv HBIgB (n=299) sc HBIg (n=236) Other HBIgs (n=130)
Duration of exposure, months
 Mean ±SD
 Median (range)
31±37
14 (0–176)
36±19
35 (4–117)
42±33
37 (0–159)
Total duration of treatment, months 8993 8379 5392
Time to first treatment, days post-LT
 Mean ±SD
 Median (range)
22±139
1 (1–1691)
1349±1331
847 (1–5347)
548±913
208 (1–5029)
Daily dose during treatment, IUa
 Mean ±SD
 Median (range)
1658±2902
238 (12–10 000)
71±28
71 (16–143)
181±669
71 (16–5000)
Table 2. Hepatitis B immunoglobulin (HBIg) formulations and antiviral treatment after liver transplantation.
a Including all treatment periods during documentation. LT – liver transplantation.
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post-transplant onwards, the mean dose was stable for each 
category of HBIg therapy, but remained higher for iv HBIgB 
than for sc HBIg or other HBIg products (Figure 2B). Almost 
all patients received sc HBIg at home (96.6%), compared to 
no patients given iv HBIgB and 56.9% of patients given other 
HBIg therapies.
There were no reports of HBIg-associated adverse events.
Antiviral therapy
Prior to transplantation, 217 patients (58.5%) received a NUC, 
most frequently lamivudine (n=127). After transplantation, 347 
patients (93.5%) were given at least 1 antiviral medication, 
including a NUC in each case. Lamivudine was again the most 
frequently prescribed NUC (225/272, 60.6%) (Table 1), with 
lamivudine/adefovir the most common combination of NUCs 
(12.1% of patients). Twenty patients (5.4%) received antivirals 
for reasons other than HBV prophylaxis.
Anti-HBs
At the end of the documentation period, anti-HBs test results 
were available for 317 patients, of whom 275 (86.8%) had a 
positive result. Of the 273 patients with quantitative data, 231 
(84.6%) had a serum level ³100 IU/l.
In the subgroup who were receiving HBIg therapy at the end 
of documentation and for whom data were available, 239/243 
(98.4%) were anti-HBs-positive and 204/239 (85.4%) had a 
serum level ³100 IU/l (Table 3).
HBV recurrence
The proportion of patients free of HBV recurrence was 95.7% 
(95% CI [93.1%, 97.5%]). HBV recurred in 16 patients (4.3%; 
95% CI [2.5%; 6.9%]) during the documentation period, at a 
mean (±SD) of 36.3 (±35.6) months post-transplant (median 
22.3 months, range 0.2–103.3 months) (Figure 3). Characteristics 
of the 16 patients with recurrence are shown in Table 4. The 
immunosuppression regimen immediately after liver trans-
plantation in this subgroup included calcineurin inhibition in 
15/16 cases (93.8%), mycophenolate mofetil in 4/16 cases 
(25.0%), azathioprine in 4/16 cases (25.0%), and corticoste-
roids in 10/16 cases (62.5%), with anti-IL-2 receptor antibody 
induction given to 3/16 patients (18.8%).
The rate of HBV recurrence per year was 0.65% across the 
total observation period.
LT
10.000
8.000
6.000
4.000
2.000
0
3
Time post-transplant (months)
M
ea
n 
(S
D)
 da
ily
 do
se
, IU iv HBIgB
sc HBIg
Other HBIg
Any HBIg
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Figure 2.  Mean [SD] daily dose of hepatitis B immunoglobulin (HBIg) therapies (A) from time of liver transplantation (LT) to month 
3 post-transplant, (B) from month 3 post-transplant therapies to end of documentation (EOD) in patients transplanted for 
hepatitis B virus (HBV)-related disease. Data are shown for any HBIg therapy and for iv HBIgB, sc HBIg, and other HBIg 
products. LT was defined as day of LT and up to 7 days after LT.
N=270
Status
 No. patients with data 243
 Anti-HBs-positive, n/N (%) 239/243 (98.4)
 Anti-HBs-negative, n/N (%) 4/243 (1.6)
 Missing, n/N (%) 27/270 (10.0)
Serum level
 No. patients with data 239
 ³100 IU/l, n/N (%) 204/239 (85.4)
 <100 IU/l, n/N (%) 35/239 (14.6)
 Mean ±SD, IU/l 204±137
 Median (range), IU/l 188 (10–1024)
 Missing, n/N (%) 31/270 (11.5)
Table 3.  Anti-HBs test results at the end of the documentation 
period in patients receiving hepatitis B immunoglobulin 
(HBIg) treatment at final documentation.
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Among patients with HBV recurrence for whom pre-transplant 
HBV test results were available, 12/12 were HBsAg-positive 
and 8/12 were HBV DNA-positive. Hepatitis D virus (HDV) 
co-infection was present in 4/16 patients who experienced 
HBV recurrence (Table 4). Thus, HBV recurrence occurred in 
4/114 (3.5%) of HDV-co-infected patients over the whole doc-
umentation period and in 0.5% patients per year.
The duration of exposure to sc HBIg or other HBIg therapies, 
but not iv HBIgB, was shorter in patients with HBV recurrence 
versus those without recurrence (Table 5). Eleven of the 16 pa-
tients with HBV recurrence were receiving HBIg therapy at time 
of recurrence (6 iv HBIgB, 1 sc HBIg, 4 other HBIg) (11/371, 3.0%) 
(Figure 4). The remaining 5 patients were not receiving HBIg (2 
had stopped treatment <3 months previously). When HBV recur-
rence was analyzed according to the time during which patients 
were on HBIg treatment (22 764 months) or not on treatment 
(8017 months), there was 1 on-treatment recurrence per 2069 
months of treatment (11/22 764) and 1 recurrence while not on 
HBIg therapy per 1603 months without treatment (5/8017). In 
patients who stopped HBIg treatment compared to those given 
sc HBIg, the risk of developing HBV recurrence was increased by 
a factor of 5.2 (1 per 1603 versus 1 per 8379 treatment months).
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Figure 3.  Time to first hepatitis B virus (HBV) recurrence in the 
16 patients who developed HBV recurrence out of 371 
patients (4.3%) transplanted for HBV-related disease.
Patient
Time to 
recurrence 
(months) 
Treatment at time 
of recurrence
Determination of first 
HBV recurrence
Risk factors at time of LT
HBIg
Anti-HBs level 
(IU/l)
Antiviral 
therapy
HBV DNA 
(copies/ml)
HBs Ag
HBV DNA/HBsAg 
(copies/ml IU/ml)
HCC
HDV co-
infection
#1 6.2 iv HBIgB NA LAM NA + ND/+ – –
#2 46.2 iv HBIgB NA LAM 5.6×103 NA NA/NA – –
#3 0.7 iv HBIgB >100 (1000) TDF 1.85×102 NA 8.5×104/+ – –
#4 0.2 iv HBIgB NA TDF 2.1×102 ND 6.5×105/+ – –
#5 64.4 iv HBIgB >100 (178) TDF, ETV 9.82×105 + 3.66×107/+ – +
#6 13.0 iv HBIgB <100 (61) LAM + + NA/+ + –
#7 77.4 sc HBIg <100 (18) LAM, ADV ND + NA/+ + +
#8a 18.9 Other HBIg <100 (3) LAM, ADV ND + ND/250 + –
#9a 12.3 Other HBIg <100 (18) LAM, ADV 2.95×103 + ND/250 + –
#10 102.3  Other HBIg NA –  2.75×102 NA NA/NA – +
#11 64.4  Other HBIg NA – 50 ND 8.1×102/NA + +
#12 103.3 No HBIg NA TDF ND + 5.93×103/+ – –
#13 15.6 No HBIg <100 (ND) LAM 6.65×104 + 4.14×104/+ + –
#14 25.6 No HBIg <100 (ND) – 6.64×107 + ND/236 – –
#15 0.8 No HBIg NA LAM 60 NA 7.5×104/NA + –
#16 29.0 No HBIg <100 (ND) LAM, ADV + + +/+ – –
Table 4. Characteristics of patients with HBV recurrence (n=16).
a Concomitant HBV-HCC recurrence also occurred. ADV – adefovir; ETV – entecavir; HBIg – hepatitis B immunoglobulin; HCC – 
hepatocellular carcinoma; HDV – hepatitis D virus; LAM – lamivudine; LT – liver transplantation; NA – not available; ND – not 
detectable; TDF – tenofovir disoproxil fumarate.
795
Beckebaum S. et al.: 
HBV recurrence with hepatitis B immunoglobulin prophylaxis
© Ann Transplant, 2018; 23: 789-801
ORIGINAL PAPER
Indexed in: [Science Citation Index Expanded] [Index Medicus/MEDLINE] 
[Chemical Abstracts] [Scopus]
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
The serum anti-HBs level at time of recurrence was available 
in 10/16 patients, 7 of whom had a level <100 IU/l (with 6 
patients <50 IU/l) (Table 6). Among these 7 patients, the HBIg 
treatment was iv HBIgB in 1 case, sc HBIg in 1 case, other HBIgs 
in 2 cases, and no HBIg in 3 cases. Seven of the remaining 9 
patients were receiving HBIg at the time of recurrence, 2 of 
whom were known to have serum anti-HBs ³100 IU/l. Assuming 
conservatively that the other 5 patients also had serum anti-
HBs ³100 IU/l, the rate of recurrence in adequately-treated 
patients was 1.9% (7/371) (Figure 4). No patient switched to 
adequate treatment with sc HBIg had recurrent HBV.
At time of recurrence, 13/16 patients were under NUC treat-
ment. Recurrences were observed in patients receiving NUC 
alone, HBIg with lamivudine, and HBIg with adefovir, but also 
when HBIg was given in combination with more potent NUCs 
(Table 4).
Graft rejection
Acute rejection occurred in 37/371 (10.0%) of patients and 
chronic rejection occurred in 7/371 (1.9%) of patients.
HBV-HCC recurrence
HBV-HCC recurred in 14/147 (9.5%; 95% CI [5.3%, 15.5%]) of 
patients transplanted due to HBV-HCC. The annual rate of re-
currence was 1.7% and the mean (±SD) time to recurrence 
was 17.6 (±10.8) months (median 14.1 months, range 5.5–41.9 
months) (Figure 5A).
Characteristics of the patients with HBV-HCC recurrence are 
shown in Table 6. Each of these 14 patients had HBV-HCC 
within Milan criteria confirmed by histopathology at the time 
iv HBIgB sc HBIg Other HBIgs
No HBV recurrence (n=355)
 Mean, months ±SD
 Median months (range)
n=283
31±37
13 (0–176)
n=233
37±18
35 (4–117)
n=120
44±34
39 (0–159)
HBV recurrence (n=16)
 Mean months ±SD
 Median months (range)
n=16
29±31
23 (1–102)
n=3
14±7
13 (9–22)
n=10
23±22
15 (0–63)
No HBV-HCC recurrence (n=357)
 Mean months ±SD
 Median months (range)
n=289
32±38
14 (0–176)
n=230
37±18
35 (4–117)
n=121
44±34
41 (0–159)
HBV-HCC recurrence (n=14)
 Mean, months ±SD
 Median, months (range)
n=10
9±8
7 (0.2–24)
n=6
23±20
18 (7–60)
n=9
16±9
15 (7–36)
Table 5.  Duration of hepatitis B immunoglobulin (HBIg) therapy in patient subgroups that received either of the indicated HBIgs at any 
time point during the observation period.
HBV – hepatitis B virus; HBV-HCC – HBV-related hepatocellular carcinoma; SD – standard deviation
4.3%
All treatments
(n=16)
* Serum anti-HBs data available for 2/7 patients; 
a serum anti-HBs level ≥100 IU/I was assumed for 5/7 patients
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Figure 4.  Rate of HBV recurrence according to type and 
adequacy of hepatitis B immunoglobulin (HBIg) 
treatment, based on the total population of 371 
patients transplanted for HBV-related disease. HBIg 
included iv HBIgB, sc HBIg, or other licensed HBIg 
preparations. ‘All treatment’ includes all patients who 
developed HBV recurrence regardless of the type or 
duration of HBIg treatment; ‘Patients under HBIg’ 
includes all patients who developed HBV recurrence 
while receiving HBIg therapy; ‘Patients under HBIg 
with adequate treatment’ includes all patients who 
developed HBV recurrence while receiving any HBIg 
therapy and who had a serum level of anti-HBs ³100 
IU/l; ‘Patients under sc HBIg with adequate treatment’ 
includes all patients who developed HBV recurrence 
while receiving sc HBIg therapy and who had a serum 
level of anti-HBs ³100 IU/l. If the serum anti-HBs level 
was not available, it was assumed conservatively to be 
³100 IU/l for the purposes of analysis.
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Figure 5.  (A) Time to first recurrence of hepatitis B virus (HBV)-hepatocellular carcinoma (HBV-HCC) in the 14 patients (14/147, 9.5%) 
transplanted for HCC and who had HBV-HCC recurrence, (B) time to first occurrence of de novo non-HCC cancer in the 
26 patients (26/371, 7.0%) transplanted for HBV-related disease who developed a de novo non-HCC cancer.
Patient
Year of 
recur-
rence
Time to 
recurrence 
[months]
Treatment at time of 
HBV-HCC recurrence
Manifestation 
of HBV-HCC 
recurrence
Number of 
nodules/total 
size [cm]
Treatment before  
liver transplant
Down-
staging
#1 2009 15.7 iv HBIgB LAM, ADV Extrahepatic NA/NA RFA No
#2a 2005 7.8 iv HBIgB LAM, ADV Extrahepatic 1/2 TACE Yes
#3 2005 23.2 iv HBIgB LAM Liver 1/7 TACE No
#4 2014 12.4 sc HBIg LAM Extrahepatic Multiple/NA TACE No
#5 2011 31.3 sc HBIg LAM
Liver &  
extrahepatic
NA/NA n.a. No
#6 2015 10.2 sc HBIg ETV
Liver &  
extrahepatic
NA/NA RFA/SOR No
#7 2012 16.2 sc HBIg ETV Extrahepatic NA/NA
TACE/ 
resection
Yes
#8 2014 8.1 sc HBIg TDF Extrahepatic NA/NA RFA Yes
#9a,b 2007 18.9 Other HBIg LAM, ADV Liver 1/3 TACE Yes
#10b 2006 12.1 Other HBIg LAM
Liver &  
extrahepatic
2/10 TACE No
#11 2012 42.0 Other HBIg LAM
Liver &  
extrahepatic
1/1.8 n.a. n.a.
#12 2009 5.5 Other HBIg LAM
Liver &  
extrahepatic
Multiple/8 TACE Yes
#13 2013 11.0 Other HBIg TDF Liver 1/3.3 RFA/TA Yes
#14 2015 32.3 No HBIg ETV Extrahepatic 1/0.5 TACE/RFA Yes
Table 6. Characteristics of patients with HBV-HCC recurrence (n=14).
a Outside the Milan criteria at time of transplant as determined by the radiological report, but this was not confirmed by later 
histopathology. b Concomitant HBV recurrence. ADV – adefovir; ETV – entecavir; HBIg – hepatitis B immunoglobulin; HBV – hepatitis 
B virus; HCC – hepatocellular carcinoma; LAM – lamivudine; NA – not available; n.a. – not applicable; RFA – radiofrequency ablation; 
SOR – sorafenib; TACE – transarterial chemoembolization; TDF – tenofovir disoproxil fumarate.
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of transplantation. Two of the patients also experienced HBV 
recurrence. Two patients had concomitant alcoholic liver dis-
ease and 3 patients had HDV co-infection. HCC recurrence oc-
curred in 3/37 (8.1%) patients co-infected with HDV. The diag-
nosis of recurrence was based on clinical/radiological findings 
in 8 cases, with histopathological evidence in 7 cases (confir-
mation was by both methods in 1 case).
For all 3 categories of HBIg, the mean duration of HBIg 
therapy was shorter among patients with HBV-HCC recurrence 
(9, 23, and 16 months for iv HBIgB, sc HBIg, and other HBIgs, 
respectively) versus patients without HBV-HCC recurrence (32, 
37, and 44 months, respectively) (Table 5). Documentation in 
patients with HBV or HCC recurrence was stopped at the time 
of determination, which led to a shorter documentation time 
in these patients. At the time of recurrence, 8 patients were 
receiving either iv HBIgB or sc HBIg, 5 were being treated with 
another HBIg, and 1 was not receiving HBIg therapy. All 14 
patients were being treated with antivirals, most frequently 
lamivudine (9/14) (Table 6).
De novo malignancies other than HCC
In total, 26/371 patients (7.0%; 95% CI [4.6%, 10.1%]) were 
diagnosed with de novo malignancies during the documen-
tation period, representing an incidence of 1.05% per year. 
The most frequent of these were skin cancers (squamous cell 
carcinoma n=3, basal cell carcinoma n=2, cutaneous carcinoma 
n=2). Kaposi’s sarcoma and lung cancer occurred in 2 patients 
each; no other cancer occurred in more than 1 patient. The 
mean (±SD) time to onset was 59.4 (±40.7) months (median 
61.4; range 0.8–141.7 months) (Figure 5B). At the time of 
diagnosis, 16 patients were receiving HBIg therapy and 10 pa-
tients had stopped HBIg treatment. The incidence of de novo 
malignancies in the cohort of patients with HCC recurrence 
was 12.5% (2/16 patients).
Discussion
This retrospective analysis represents one of the largest data 
sets available to determine HBV recurrence rates in HBV-
infected patients after liver transplantation and explore HCC 
recurrence in this population. In this European multicenter 
study, combination prophylaxis with HBIg and NUC therapy 
was associated with low rates of HBV recurrence (4.3%) over 
a mean follow-up of almost 7 years. The HBV-HCC recurrence 
rate was 9.5%.
A recent systematic review which pooled data from 17 ran-
domized or observational studies found the HBV recurrence 
rate to be 7.1% for patients treated with HBIg and lamivudine, 
or 1.3% with HBIg and either entecavir or tenofovir (there was 
no restriction of HBIg duration in either group) [10]. The latter 
rate is strikingly lower, but comparison with the recurrence rate 
in the present study (4.3%) is difficult because the follow-up 
periods differ markedly, with a mean of ~3 years in the pooled 
analysis compared to 6.8 years in the present study. HBV re-
currence has been reported to occur most frequently at ap-
proximately 2–4 years post-transplant [8,11], consistent with 
our observation (mean 36±36 months).
NUC therapy alone, however, has also been explored. Recently, 
an observational study of 265 Asian liver transplant patients 
with chronic HBV infection was published, in which patients 
received entecavir without HBIg therapy [12]. During a max-
imum follow-up of 8 years, 14/265 (5.3%) patients remained 
persistently positive for HBsAg. Among 242 patients who ex-
perienced HBsAg seroclearance after transplantation, 36 devel-
oped HBsAg and none had HBV DNA reappearance. This cor-
responds to a recurrence rate of 14.8% (36/242), considerably 
higher than in our study. However, in the Asian population, 
no HDV-co-infected patient was included, in contrast to our 
European cohort in which the proportion with HDV infection 
was relatively high. In our study, the HBV recurrence rate was 
3.5% for HDV-co-infected patients, a subgroup in whom life-long 
combination therapy with HBIg and NUC is recommended [5].
In the present series, 5 of the 16 patients with HBV reinfection 
had stopped HBIg therapy by the time of recurrence. Notably, 
7 patients had documented inadequate HBIg therapy (6 of 
those had serum anti-HBs <50 IU/l and 1 had <100 IU/l). The 
threshold of ³100 IU/l is defined by the European Medicines 
Agency Committee for Medicinal Products for Human Use as 
the minimum threshold for effective protection against HBV 
reinfection using HBIg therapy [13]. Excluding the 7 patients 
in whom an inadequate serum anti-HBs level (<100 IU/l) was 
confirmed, the reinfection rate was only 2.4% of all 371 pa-
tients at risk. Higher HBIg dosage is associated with a lower 
frequency of HBV recurrence even in patients receiving com-
bination prophylaxis [7]. When dosed correctly, HBIg is highly 
effective in maintaining adequate titers [14,15]. In the present 
cohort, 14.6% of patients had a serum anti-HBs level <100 IU/l, 
suggesting failure to maintain protective titers in this sub-
population. Withdrawal of HBIg in low-risk patients after a 
defined course of combined therapy, or use of low-dose or 
on-demand HBIg therapy, are valid strategies to reduce treat-
ment costs [16,17]. Typically, transplant centers administer 
higher HBIg doses during the anhepatic phase and the very 
early phase post-transplant. Various HBIg minimization strat-
egies are then pursued [18]. However, patients must be eval-
uated carefully before HBIg reduction, based on risk fac-
tors such as high pre-transplant HBV DNA, co-infections, and 
transplantation for concomitant HBV-HCC [16,17]. According 
to EASL 2017 guidelines, discontinuation should be restricted 
to patients who were HBV DNA-negative pre-transplant [5]. 
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Here, the shorter duration of exposure to HBIg in patients 
with HBV recurrence compared to recurrence-free patients is 
of interest. The observational study design, however, does not 
permit firm conclusions from this finding; for example, HBIg 
therapy may have been discontinued after diagnosis of HBV 
recurrence. Another interesting finding is that, despite some 
missing values, patients with HBV recurrence had higher HBV 
DNA levels prior to liver transplantation (median HBV DNA 
levels were 2 log copies/mL, and only 1 of the patients with 
recurrence had DNA levels below 2 log copies/mL). This is a 
risk factor influencing recurrence in some patients.
A prospective study showed that early switch to subcutaneous 
treatment with sc HBIg (days 8–18 post-transplant), dosed 
according to serum anti-HBs level in patients who were HBV-
DNA-negative at time of transplant, maintained serum anti-HBs 
levels ³100 IU/l and no patient developed reinfection [19]. It 
is striking in the present series that there was only 1 patient 
with HBV recurrence over a total of 8379 months of sc HBIg 
treatment. Sub-optimal dosing with sc HBIg may be responsible 
for this single occurrence, as the anti-HBs level of 18 IU/l was 
below the minimum threshold for effective protection. In terms 
of dosing, the median daily dose of sc HBIg over the entire study 
duration was lower than with iv HBIgB (71 versus 238 IU). This 
partly reflects the delayed starting time for sc HBIg compared 
to iv HBIgB, but a dosing difference was sustained even after 
the early post-transplant period (Figure 2B). sc HBIg was not 
licensed until 2009, when initiation of therapy was approved at 
month 6 after transplantation. It was not until late 2015 that 
a change in the labeling allowed initiation of therapy as early 
as 1 week post-transplantation. By this time, the last patient 
included in this study had already been transplanted.
The annual incidence of HCC recurrence in the present study 
was very low, at 1.7%. This compares favorably with rates of 
3.2–6.7% reported elsewhere [8,12,20,21]. It is possible that 
factors such as tumor history (which was not captured by the 
present study), tumor stage at transplantation, differences in 
malignancy surveillance, and the period of transplantation may 
account for this difference. HBIg treatment may positively in-
fluence the risk of HBV-HCC recurrence after liver transplant, 
in particular for HCC patients within the Milan criteria [11]. 
Observational studies have shown an association between 
HBV recurrence and HBV-HCC recurrence after transplanta-
tion [20,22,23]. In addition, high HBV viral load is an indepen-
dent risk factor for HBV-HCC recurrence [24]. These factors may 
explain why 2 patients with HBV recurrence also experienced 
HCC recurrence in our study; however, this remains speculative. 
High-dose HBIg may reduce the risk for HBV-HCC recurrence in 
patients who meet the Milan criteria [12]. In HDV-co-infected 
patients, the HCC recurrence rate was 8.1%, suggesting that 
HCC recurrence does not occur at any higher frequency in this 
high-risk group using HBIg and NUC combination prophylaxis.
The incidence of skin cancer and lymphoma in liver transplant 
patients is substantially increased compared to in healthy indi-
viduals [25,26]. Published reports of the incidence of de novo 
malignancy after liver transplantation vary widely, from 2.6% 
to 15.7% [27], influenced by risk factors such as older age [28], 
smoking [28,29], transplantation for alcoholic cirrhosis [27], 
and more intensive immunosuppression [30,31]. Against this 
background, the low rate of de novo malignancies observed 
here over this long-term follow-up, at an annual incidence of 
1.05%, is encouraging but might be an underestimation due 
to the study design. Although numbers were small, results in 
our population did not appear to indicate any marked increase 
in risk among patients with HCC recurrence compared to the 
overall population.
In this series, there was a 10% incidence of acute rejection, 
which is relatively low for a mean follow-up period of almost 7 
years. Long-term follow-up data from randomized trials have re-
ported 5-year rejection rates of 11–18% [32,33]. Patients trans-
planted for chronic HBV-related disease have been reported 
to be at lower risk for acute rejection versus non-HBV indica-
tions [34–36]. There are limited in vitro data suggesting that 
HBIg may inhibit alloantigen specific T cell responses, dendritic 
cell maturation, and cytokine production [35]. A recent study 
[37], albeit with lower HBIg concentrations as in prior in vitro 
studies [38,39], found no enhancing role on regulatory T cell 
generation. However, more in vivo and in vitro data are needed 
to determine the possible immunosuppressive effect of HBIg.
Administration of HBIg in combination with NUC was well 
tolerated and no HBIg-related adverse events were reported. 
These findings are consistent with prospective and retrospec-
tive studies of combined post-transplant prophylaxis with HBIg 
and NUC therapy [40].
Some characteristics of the present study should be considered. 
The analysis was restricted to patients with a minimum of 
1 year’s HBIg therapy (and at least 6 months under either iv 
HBIgB or sc HBIg), but this applied to nearly all cases trans-
planted at the study centers over the period of documentation. 
The findings cannot be extrapolated to shorter periods of HBIg 
treatment. As a retrospective analysis, serological tests, notably 
anti-HBs levels, were missing or incomplete in some patients 
and differences in treatment protocols made comparisons 
between specific therapies impractical. It would have been 
relevant to document levels of anti-HBs routinely, but regular 
monitoring was not standard practice in this non-interven-
tional study; levels would be expected to be low at the point 
of hepatitis B recurrence diagnosis. Patient monitoring, such 
as for skin cancers, may have been less systematic than in a 
controlled trial. Inevitably, in a long-term observational study 
of this type, the dataset is not complete, thus introducing a 
potential risk of bias. However, the analysis benefitted from 
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a large ‘real-world’ population transplanted since 2000, and 
a consistent definition for HBV recurrence was applied across 
all patients. Importantly, it offers a long-term follow-up period 
of up to 15 years.
Conclusions
Results from this multicenter European retrospective analysis 
in a large series of patients undergoing liver transplantation 
for HBV-related disease indicate that routine clinical use of 
HBIg prophylaxis for a minimum of 1 year, combined with NUC 
therapy, is associated with a low rate of HBV recurrence and 
HBV-HCC recurrence over the long-term. Low recurrence rates 
were also seen in patients with HDV co-infection. These data 
support the current EASL guidelines [5] that combination ther-
apy with HBIg and NUC is an effective prophylactic strategy for 
the management of HBV infection in liver transplant recipients.
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